Eli Lilly (LLY.US) announced today it will suspend all investments, promotional activities and export of non-essential medicines to Russia. Also the company does not plan to start new clinical studies in the country. Drugmaker will still provide medication for patients who suffer from cancer and diabetes, however will donate all profits from ongoing Russian operations for humanitarian purposes. Other drugmakers and medical device makers took similar approaches pointing to international humanitarian law under which they are responsible to continue supplying medicines to the country.
Eli Lilly (LLY.US) stock price suffered a downward correction at the beginning of the year, however buyers managed to halt declines around support at $232.00, which is marked with a lower limit of the 1:1 structure. Next buyers took the initiative and price broke above the local resistance at $247.20 which coincides with 50 SMA (green line), 200 SMA (red line) and 23.6% Fibonacci retracement of the upward wave launched in October 2020. If current sentiment prevails, upward move may accelerate towards all-time high around $285.00. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
